-
Innovation Ranking
NewInnovation Ranking – Synlogic Inc
Synlogic Inc (Synlogic), formerly TMC Therapeutics Inc, is a clinical stage drug development company that develops novel class of living medicines for the treatment of rare and genetic metabolic diseases. The company’s pipeline includes SYNB1618 to treat the Phenylketonuria. It also produces drugs based on its proprietary synthetic biology and microbiome platform for the treatment of diseases, including liver disease, inflammatory and immune disorders, and cancer. The company's synthetic biotics are designed to make therapeutic effects throughout the body from...
-
Product Insights
NewNet Present Value Model: Synlogic Inc’s SYNB-8802
Empower your strategies with our Net Present Value Model: Synlogic Inc's SYNB-8802 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tagraxofusp in Systemic Mastocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tagraxofusp in Systemic Mastocytosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tagraxofusp in Systemic Mastocytosis Drug Details: Tagraxofusp (Elzonris) acts as an...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ibrutinib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibrutinib in Metastatic Breast Cancer Drug Details: Ibrutinib (Imbruvica) is an...
-
Product Insights
Gouty Arthritis (Gout) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gouty Arthritis (Gout) - Drugs In Development, 2023’, provides an overview of the Gouty Arthritis (Gout) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hyperoxaluria – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperoxaluria - Drugs In Development, 2023’, provides an overview of the Hyperoxaluria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...